Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Seikagaku Nets Positive Data in Additional US PIII for Herniated Disk Drug
Seikagaku said on May 26 that its investigational agent SI-6603 (condoliase) has delivered positive results in an additional PIII study conducted in the US for the treatment of lumbar disc herniation. The study was a randomized, double-blind, sham-controlled trial, which…
To read the full story
Related Article
- Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20, 2018
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…